Athenex (ATNXQ) 10-Q 14 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 02, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Trading Symbol	ATNX
Entity Registrant Name	Athenex, Inc.
Entity Central Index Key	1,300,699
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		66,893,883

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 51,108	$ 39,284
Short-term investments	90,309	11,753
Accounts receivable, net of chargebacks and other deductions of $13,154 and $3,711, respectively, and allowance for doubtful accounts of $27 and $84, respectively	7,071	8,468
Inventories	25,231	16,561
Prepaid expenses and other current assets	13,983	7,692
Total current assets	187,702	83,758
Property and equipment, net	11,174	9,651
Investment	399	328
Goodwill	37,501	37,795
Intangible assets, net	7,254	8,572
Deferred income tax assets	437	121
Other long-term assets		188
Total assets	244,467	140,413
Current liabilities:
Accounts payable	12,694	16,659
Accrued expenses	28,060	25,776
Deferred revenue	364	1,202
Current portion of long-term debt - related parties		491
Current portion of long-term debt	978	1,015
Total current liabilities	42,096	45,143
Long-term liabilities:
Deferred compensation	2,678	2,313
Deferred rent	2,087	1,760
Capital lease obligations	424	475
Long-term debt	45,125
Total liabilities	92,410	49,691
Commitments and contingencies (See Note 13)
Stockholders' equity:
Common stock, par value $0.001 per share, 250,000,000 shares authorized at September 30, 2018 and December 31, 2017; 68,561,678 and 59,894,362 shares issued at September 30, 2018 and December 31, 2017, respectively; 66,888,758 and 58,221,442 shares outstanding at September 30, 2018 and December 31, 2017, respectively	68	60
Additional paid-in capital	587,155	423,805
Accumulated other comprehensive (loss)	(620)	(146)
Accumulated deficit	(416,603)	(326,276)
Less: treasury stock, at cost; 1,672,920 shares at September 30, 2018 and December 31, 2017	(7,406)	(7,406)
Total Athenex, Inc. stockholders' equity	162,594	90,037
Non-controlling interests	(10,537)	685
Total stockholders' equity	152,057	90,722
Total liabilities and stockholders' equity	$ 244,467	$ 140,413

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Accounts receivable, chargebacks and other deductions (in dollars)	$ 13,154	$ 3,711
Allowance for doubtful accounts (in dollars)	$ 27	$ 84
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	68,561,678	59,894,362
Common Stock, shares outstanding	66,888,758	58,221,442
Treasury stock, shares	1,672,920	1,672,920

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue:
Total revenue	$ 18,428	$ 13,994	$ 67,829	$ 23,170
Costs and operating expenses:
Cost of sales	11,965	8,082	32,734	15,058
Research and development expenses (See Note 6)	51,204	11,944	99,077	55,949
Selling, general, and administrative expenses	11,493	10,364	37,390	33,795
Total costs and operating expenses	74,662	30,390	169,201	104,802
Operating loss	(56,234)	(16,396)	(101,372)	(81,632)
Interest expense	1,058	353	463	6,010
Loss on derivative liability		6,548		15,411
Loss before income tax benefit	(57,292)	(23,297)	(101,835)	(103,053)
Income tax (benefit) expense	(30)	11	(286)	(52)
Net loss	(57,262)	(23,308)	(101,549)	(103,001)
Less: net loss attributable to non-controlling interests	(11,091)	(34)	(11,222)	(114)
Net loss attributable to Athenex, Inc.	(46,171)	(23,274)	(90,327)	(102,887)
Unrealized (loss) gain on investment, net of income taxes	(37)	4	3	(30)
Foreign currency translation adjustment, net of income taxes	(554)	242	(477)	922
Comprehensive loss	$ (46,762)	$ (23,028)	$ (90,801)	$ (101,995)
Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted (See Note 10)	$ (0.70)	$ (0.41)	$ (1.42)	$ (2.18)
Weighted-average shares used in computing net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted (See Note 10)	66,399,091	57,134,889	63,806,787	47,238,452
Product Sales, Net
Revenue:
Total revenue	$ 13,309	$ 13,662	$ 37,385	$ 21,978
License Fees and Consulting Revenue
Revenue:
Total revenue	5,096	60	30,278	756
Grant Revenue
Revenue:
Total revenue	$ 23	$ 272	$ 166	$ 436

Condensed Consolidated Statemen

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive (Loss)	Treasury Stock	Total Athenex, Inc. Stockholders' Equity	Non-Controlling Interests
Beginning Balance at Dec. 31, 2016	$ 34,669	$ 42	$ 237,581	$ (195,106)	$ (1,304)	$ (7,406)	$ 33,807	$ 862
Beginning balance, shares at Dec. 31, 2016		42,342,706				(1,656,920)
Sale of common stock	64,194	$ 7	64,187				64,194
Sale of common stock, shares		6,900,000
Conversion of bonds	98,929	$ 9	98,920				98,929
Conversion of bonds, shares		8,522,728
Stock-based compensation cost	10,090		10,090				10,090
Stock-based compensation cost, shares		400,000
Research and development license purchased with stock	6,250	$ 1	6,249				6,250
Research and development license purchased with stock, shares		568,182
Vesting of restricted stock	1,620	$ 1	1,619				1,620
Vesting of restricted stock, shares		421,982
Stock options and warrants exercised	1,208		1,208				1,208
Stock options and warrants exercised, shares		512,586
Repurchase of common stock, shares						(16,000)
Non-controlling interests	49							49
Net loss	(103,001)			(102,887)			(102,887)	(114)
Other comprehensive income (loss), net of tax	892				892		892
Ending balance at Sep. 30, 2017	114,900	$ 60	419,854	(297,993)	(412)	$ (7,406)	114,103	797
Ending balance, shares at Sep. 30, 2017		59,668,184				(1,672,920)
Beginning Balance at Dec. 31, 2017	90,722	$ 60	423,805	(326,276)	(146)	$ (7,406)	90,037	685
Beginning balance, shares at Dec. 31, 2017		59,894,362				(1,672,920)
Sale of common stock	117,148	$ 7	117,141				117,148
Sale of common stock, shares		7,444,528
Issuance of warrants	3,140		3,140				3,140
Stock-based compensation cost	7,558		7,558				7,558
Research and development license purchased with stock	31,545		31,545				31,545
Research and development license purchased with stock, shares		375,133
Vesting of restricted stock	1,007		1,007				1,007
Vesting of restricted stock, shares		240,000
Stock options and warrants exercised	2,960	$ 1	2,959				2,960
Stock options and warrants exercised, shares		607,655
Net loss	(101,549)			(90,327)			(90,327)	(11,222)
Other comprehensive income (loss), net of tax	(474)				(474)		(474)
Ending balance at Sep. 30, 2018	$ 152,057	$ 68	$ 587,155	$ (416,603)	$ (620)	$ (7,406)	$ 162,594	$ (10,537)
Ending balance, shares at Sep. 30, 2018		68,561,678				(1,672,920)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Statement Of Stockholders Equity [Abstract]
Stock issuance costs and discounts	$ 5,518	$ 11,706

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash flows from operating activities:
Net loss	$ (101,549)	$ (103,001)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,424	2,585
Stock-based compensation expense	8,659	11,710
Change in fair value of derivative liability		15,411
Amortization of debt discount	256	3,349
Deferred rent expense	329	640
(Gain) loss on disposal of assets and impairment charges	(62)	80
Research and development license purchased with convertible bond and stock	31,545	13,250
Interest incurred on converted bonds		2,759
Deferred income taxes	(316)	(108)
Changes in operating assets and liabilities:
Receivables, net	1,397	(3,682)
Prepaid expenses and other assets	(6,290)	(2,722)
Inventories	(8,670)	(7,395)
Accounts payable and accrued expenses	(3,038)	3,480
Net cash used in operating activities	(75,315)	(63,644)
Cash flows from investing activities:
Purchase of property and equipment	(2,501)	(4,384)
Receipt of deposit		80
Payments for licenses		(1,550)
Purchases of short-term investments	(110,605)	(55,282)
Sale of short-term investments	31,981	14,114
Net cash used in investing activities	(81,125)	(47,022)
Cash flows from financing activities:
Proceeds from sale of stock	122,666	75,900
Proceeds from issuance of debt	50,000	30,000
Costs incurred related to the sale of stock	(5,118)	(10,168)
Costs incurred related to the issuance of debt	(1,593)
Proceeds from exercise of stock options	2,960	1,208
Investment from non-controlling interest		49
Repayment of capital lease obligations and long-term debt	(551)	(896)
Net cash provided by financing activities	168,364	96,093
Net increase (decrease) in cash and cash equivalents	11,924	(14,573)
Cash and cash equivalents, beginning of period	39,284	33,125
Effect of exchange rate changes on cash and cash equivalents	(100)	710
Cash and cash equivalents, end of period	51,108	19,262
Non-cash investing and financing activities:
Accrued purchases of property and equipment	445	150
Cost of equity in accounts payable and accrued expenses	400
Convertible bond issued in lieu of licensing cash payment		7,000
Common stock issued for purchase of license (See Note 6)	$ 31,545	6,250
Common stock issued upon the conversion of bonds		98,929
Property and equipment financed under capital lease		$ 242

Company and Nature of Business

Company and Nature of Business	9 Months Ended
	Sep. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Company and Nature of Business	1. Company and Nature of Business Organization and Description of Business Athenex, Inc. (the “Company” or “Athenex”) is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer through its Orascovery and Src Kinase Inhibition research platforms. The Company originally formed under the name Kinex Pharmaceuticals LLC (“Kinex”) in November 2003, commenced operations on February 5, 2004, and operated as a limited liability company until it was incorporated in the State of Delaware under the name Kinex Pharmaceuticals, Inc. on December 31, 2012. The Company changed its name to Athenex, Inc. on August 26, 2015. The Company’s primary activities since inception have been conducting research and development activities internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, and conducting preclinical and clinical testing, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development activities. In addition to licensing and consulting revenue, the Company also generates revenue from its commercial and global supply chain platforms. See Note 12 – Revenue Recognition. Initial Public Offering In June 2017, the Company completed its initial public offering (“IPO”) on the Nasdaq Global Select Market. An aggregate of 6,900,000 shares of its common stock were sold at $11.00 per share for cash proceeds of $64.2 million, net of underwriting discounts and commissions of $6.1 million and offering costs of $5.6 million. In connection with the IPO, convertible bonds with an aggregate principal value of $68.0 million, and a carrying value of $55.8 million, were converted into 7,727,273 shares of common stock. In September 2017, the remaining convertible bond with a principal value of $7.0 million was converted into 795,455 shares of common stock, at a 20% discount from the IPO price. Follow-On Offering In January 2018, the Company completed an underwritten public offering of 4,300,000 shares of its common stock. The Company granted the underwriters a 30-day option to purchase up to an additional 645,000 shares of common stock. In February 2018, the underwriters partially exercised their option, purchasing an additional 465,000 shares of common stock. All shares were offered by the Company at a price of $15.25 per share. Net proceeds were $68.1 million, after deducting underwriting discounts and commissions and offering expenses of $4.6 million. Debt and Equity Offering On July 3, 2018, the Company closed a privately placed debt and equity financing deal with Perceptive Advisors LLC and its affiliates (“Perceptive”) for gross proceeds of $100.0 million and received aggregate net proceeds of $97.1 million, net of fees and offering expenses. The Company entered into a 5-year senior secured loan for $50.0 million of this financing and issued 2,679,528 shares of its common stock at a purchase price of $18.66 per share for the remaining $50.0 million. The loan matures on the fifth anniversary from the closing date and bears interest at a floating per annum rate equal to London Interbank Offering Rates (“LIBOR”) (with a floor of 2.0%) plus 9.0%. The Company is required to make monthly interest-only payments with a bullet payment of the principal at maturity. The loan agreement contains specified financial maintenance covenants. The Company was in compliance with such covenants as of September 30, 2018. In connection with the loan agreement, the Company granted Perceptive a warrant for the purchase of 425,000 shares of common stock at a purchase price of $18.66 per share. This was accounted for as a detachable warrant at its fair value and is recorded as an increase to additional paid-in-capital on the condensed consolidated statement of stockholders’ equity. Significant Risks and Uncertainties The Company has incurred operating losses since its inception and, as a result, as of September 30, 2018 and December 31, 2017 had an accumulated deficit of $416.6 million and $326.3 million, respectively. Operations have been funded primarily through the sale of common stock and, to a lesser extent, from convertible bond financing, senior secured loan, revenue, and grant funding. The Company will require significant additional funds to conduct clinical trials and to fund its operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all. If adequate funds are not available, the Company may be required to delay, modify, or terminate its research and development programs or reduce its planned commercialization efforts. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund operations, including additional public offerings; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans and might delay, modify, or terminate its research and development programs or reduce its planned commercialization efforts. Accordingly, there is substantial doubt regarding the Company’s ability to continue as a going concern. These consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of the business. The Company’s recurring losses from operations and negative cash flows from operations have raised substantial doubt regarding its ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Athenex is subject to a number of risks similar to other biopharmaceutical companies, including, but not limited to, the lack of available capital, possible failure of preclinical testing or clinical trials, inability to obtain marketing approval of product candidates, competitors developing new technological innovations, market acceptance of the Company’s products, and protection of proprietary technology. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate sufficient product revenue and might not, if ever, achieve profitability.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments ) considered necessary for a fair presentation of the results of the Company for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been fully eliminated in consolidation. Results of the operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2018. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, allowance for doubtful accounts, inventory reserves, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates. Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and invests in highly liquid U.S. treasury notes, commercial papers and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility in China, and therefore is subject to foreign currency fluctuation. Recent Accounting Pronouncements Not Yet Adopted In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “ Leases (Topic 842) Commitments and Contingencies In June 2018, the FASB issued ASU No. 2018-07, “ Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,” Compensation – Stock Compensation,” Recently Adopted Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) No. 2014-09, “ Revenue from Contracts with Customers (Topic 606) Revenue Recognition In November 2016, the FASB issued ASU 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash In May 2017, the FASB issued ASU 2017-09, “ Stock Compensation—Scope of Modification Accounting

Inventories

Inventories	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Inventories	3. Inventories Inventories consist of the following (in thousands): September 30, 2018 December 31, 2017 Raw materials and purchased parts $ 2,778 $ 1,471 Work in progress 3,303 1,877 Finished goods 19,150 13,213 Total inventories $ 25,231 $ 16,561

Intangible Assets, net

Intangible Assets, net	9 Months Ended
	Sep. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets, net	4. Intangible Assets, net The Company’s identifiable intangible assets, net, consist of the following (in thousands): September 30, 2018 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 4,650 $ 1,836 $ — $ 2,814 Polymed customer list 1,593 873 — 720 Polymed technology 3,712 930 — 2,782 Product rights 530 231 — 299 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,026 — — 1,026 Effect of currency translation adjustment (387 ) — — (387 ) Total intangible assets, net $ 11,124 $ 3,870 $ - $ 7,254 December 31, 2017 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets Licenses $ 4,650 $ 1,173 $ — $ 3,477 Polymed customer list 1,593 675 — 918 Polymed technology 3,712 762 — 2,950 Product rights 530 132 — 398 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,106 — 80 1,026 Effect of currency translation adjustment (197 ) — — (197 ) Total intangibles, net $ 11,394 $ 2,742 $ 80 $ 8,572 As of September 30, 2018, licenses at cost include an Orascovery license of $0.4 million and licenses purchased from Gland Pharma Limited (“Gland”) of $4.3 million. The Company purchased the Orascovery license directly from Hanmi Pharmaceuticals Co. Ltd. (“Hanmi”) and is amortizing it on a straight-line basis over a period of 12.75 years, the remaining life of the license agreement at the time of purchase. The licenses purchased from Gland are being amortized on a straight-line basis over a period of five years, the remaining life of the license agreement at the time of purchase. The remaining intangible assets were acquired in connection with the acquisitions of Athenex Pharma Solutions (“APS” or “Athenex Pharma Solutions,” and formerly known as QuaDPharma), Polymed Therapeutics, Inc. (“Polymed”), and Comprehensive Drug Enterprises (“CDE”). Intangible assets are amortized using an economic consumption model over their useful lives. The APS customer list was being amortized on a straight-line basis over 7 years. The Polymed customer list and technology are amortized on a straight-line basis over 6 and 12 years, respectively. The CDE in-process research and development, (“IPR&D”), will not be amortized until the related projects are completed. IPR&D will be tested annually for impairment, unless conditions exist causing an earlier impairment test (e.g., abandonment of project). No impairment charges were recorded during the nine months ended September 30, 2018. During the nine months ended September 30, 2017, the Company abandoned a project and thus wrote off the related balance of $0.1 million as impaired and included it in the research and development expenses in the consolidated statement of operations and comprehensive loss for the nine months ended September 30, 2017. The weighted-average useful life for all intangible assets was 8.77 years as of September 30, 2018. The Company recorded $0.4 million of amortization expense for both the three-month periods ended September 30, 2018 and 2017, respectively, and $1.2 million of amortization expense for both the nine-month periods ended September 30, 2018 and 2017, respectively.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Financial instruments consist of cash and cash equivalents, short-term investments, an equity investment, accounts receivable, accounts payable, accrued liabilities, and debt. Short-term investments and the equity investment are stated at fair value. Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts. ASC 820, Fair Value Measurements, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under the ASC 820 are described as follows: Level 1 —Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2 —Inputs to the valuation methodology include: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets or liabilities in inactive markets; • Inputs other than quoted prices that are observable for the asset or liability; • Inputs that are derived principally from or corroborated by observable market data by correlation or other means; and • If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3 —Inputs to the valuation methodology are unobservable, supported by little or no market activity, and are significant to the fair value measurement. Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs. There were no transfers between Levels 1, 2 or 3 for any of the periods presented. The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at September 30, 2018 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 5,028 $ 5,028 $ — $ — Short-term investments - commercial paper 45,064 — 45,064 — Short-term investments - corporate notes 18,126 — 18,126 — Short-term investments - U.S. government bonds 32,141 — 32,141 — Investment 399 399 — — Total assets $ 100,758 $ 5,427 $ 95,331 $ — Fair Value Measurements at December 31, 2017 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 13,804 $ 13,804 $ — $ — Short-term investments - commercial paper 14,982 — 14,982 — Short-term investments - corporate notes 2,824 — 2,824 — Short-term investments - U.S. government bonds 5,006 — 5,006 — Investment 328 328 — — Total assets $ 36,944 $ 14,132 $ 22,812 $ — The Company classifies its money market funds within Level 1 because it uses quoted market prices to determine their fair value. The Company classifies its commercial paper, corporate notes, and U.S. government bonds within Level 2 because it uses quoted prices for similar assets or liabilities in active markets and each has a specified term and all Level 2 inputs are observable for substantially the full term of each instrument. The Company owns 68,000 shares of PharmaEssentia, a company publicly traded on the Taiwan OTC Exchange. As of each of September 30, 2018 and December 31, 2017, the Company’s investment in PharmaEssentia was valued at the reported closing price. This investment is classified as a Level 1 investment.

Asset Acquisition

Asset Acquisition	9 Months Ended
	Sep. 30, 2018
Asset Acquisition [Abstract]
Asset Acquisition	6. Asset Acquisition On June 29, 2018, the Company entered into a Share Subscription Agreement (“SSA”) for Axis Therapeutics (“Axis”), a subsidiary of the Company jointly owned by Athenex and Xiangxue Life Sciences Limited (“XLifeSc”). Under the SSA, Athenex contributed $30.0 million cash for a 55% ownership interest in Axis and XLifeSc contributed a license for The Company has consolidated the financial statements of Axis into its consolidated financial statements as of and for the nine months ended September 30, 2018 using the voting interest model. The nonmonetary exchange of 45% of the shares of Axis for the IPR&D from XLife has been accounted for as an asset acquisition that does not constitute a business under ASC 805. Therefore, the acquisition of IPR&D was expensed as research and development expense at its fair value. The Company determined that the fair value of the equity issued to XLifeSc was $24.5 million, considering the $30.0 million contribution made by the Company for its 55% ownership interest and the arms-length nature of the transaction. Accordingly, the Company recorded an expense of $24.5 million within research and development expenses on its consolidated statements of operations and comprehensive loss. This is a non-cash expense.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes The Company did not record a provision for federal income taxes for the nine months ended September 30, 2018 because it expects to generate a loss for the year ending December 31, 2018 and the Company’s net deferred tax assets continue to be nearly fully offset by a valuation allowance. Tax benefit to date relates to foreign tax benefit on losses in the Peoples Republic of China (“PRC”) offset by state franchise taxes and amortization of long-lived intangible assets in the U.S. and PRC.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions During the nine months ended September 30, 2018 and 2017, the Company entered into transactions with individuals and companies that have financial interests in the Company. Related party transactions included the following: a. In 2015, CDE signed an agreement with Avalon BioMedical (Management) Limited and its subsidiaries (“Avalon”) under which Avalon would receive certain administrative services and would occupy space at CDE’s research location. Avalon would reimburse CDE for these administrative services as incurred and pay CDE a percentage of the total rent payment based on its staff headcount occupying the Hong Kong research and development facility (See Note 13— Commitments and Contingencies In June 2018, the Company entered into two in-licensing agreements with Avalon wherein the Company obtained certain intellectual property from Avalon in an effort to develop and commercialize the underlying products. Under these agreements the Company is required to pay upfront fees and future milestone payments and sales-based royalties. During the nine months ended September 30, 2018, the Company recorded $5.5 million of upfront fees, consisting of $3.5 million in cash and $2.0 million in equity, as research and development expense on its condensed consolidated statement of operations and comprehensive loss. During the nine months ended September 30, 2018, 107,181 shares of common stock were issued to Avalon at a price of $18.66 per share, the closing price of the stock on the date the agreement was executed, in connection with the license agreements. b. The Company receives consulting and licensing revenue from PharmaEssentia, a company in which Athenex has an investment classified as available-for-sale (see Note 5— Fair Value Measurements c. The Company receives certain clinical development services from ZenRx Limited and its subsidiaries (“ZenRx”), a company for which one of our executive officers serves on the board of directors. In connection with such services, the Company made payments to ZenRx of d. The Company received consulting services from RSJ Consulting LLC (“RSJ”), a limited liability company for which one of our executive officers serves as the principal. Services incurred from RSJ amounted to $0 million and less than $0.1 million for the three months ended September 30, 2018 and 2017, respectively, and $0 million and $0.1 million for the nine months ended September 30, 2018 and 2017, respectively. e. During f. Certain family members of executives perform consulting services to the Company. Such services were not significant to the consolidated financial statements.

Stock Based Compensation

Stock Based Compensation	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	9. Stock-Based Compensation Common Stock Option Plans The Company has three common stock option plans adopted in 2013, 2007 and 2004 (the “Plans”) which authorize the grant of up to 11,800,000 common stock options to employees, directors, and consultants. Additionally, on June 14, 2017, the Company adopted its 2017 Omnibus Incentive Plan and 2017 Employee Stock Purchase Plan (the “2017 Plans”). Under the 2017 Plans, 5,200,000 shares of common stock were reserved for future issuance to employees, directors, and consultants, including 1,000,000 reserved for the Employee Stock Purchase Plan (“ESPP”), which was established at the time of the IPO but under which no shares have yet been issued. Stock Options The total fair value of stock options vested and recorded as compensation expense during the three months ended September 30, 2018 and 2017, and nine months ended September 30, 2018 and 2017 was $2.3 million, $2.3 million, $7.6 million, and $5.7 million, respectively. As of September 30, 2018, $20.0 million of unrecognized cost related to non-vested stock options was expected to be recognized over a weighted-average period of approximately 1.9 years. T he total intrinsic value of options exercised was approximately $6.5 million and $1.6 million for the nine months ended September 30, 2018 and 2017, respectively. The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (in thousands, except stock option amounts and exercise price): Stock Options Weighted- Average Exercise price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2017 10,176,643 $ 7.19 6.83 $ 88,615 Granted 1,411,650 17.25 Exercised (607,655 ) 5.59 Forfeited and expired (194,135 ) 10.77 Outstanding at September 30, 2018 10,786,503 $ 8.53 6.64 $ 75,562 Vested and exercisable at September 30, 2018 7,808,020 $ 6.51 5.80 $ 70,511 The Company determines the fair value of stock-based awards on the grant date using the Black-Scholes option pricing model, which is impacted by assumptions regarding a number of highly subjective variables. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated: Nine Months Ended Nine Months Ended September 30, 2018 September 30, 2017 Weighted average grant date fair value $ 9.87 $ 6.90 Expected dividend yield — % — % Expected stock price volatility 59 % 66 % Risk-free interest rate 2.60 % 1.74 % Expected life of options (in years) 6.1 6.2 Restricted Stock Restricted stock grants cliff vest on the anniversaries of their grant dates. During the nine months ended September 30, 2018, 240,000 restricted shares were vested and as of September 30, 2018, no restricted shares remained unvested. Employee Stock Purchase Plan The ESPP is available to eligible employees as defined in the plan document. Under the ESPP, shares of the Company’s common stock may be purchased at a discount (15%) of the lesser of the closing price of the Company’s common stock on the first trading or the last trading day of the offering period. The current offering period extends from July 1, 2018 to November 30, 2018. The Company expects to offer 6-month offering periods after the current period. The 2017 Plans reserved 1,000,000 shares of common stock for issuance under the ESPP. Stock-based compensation related to the ESPP amounted to $0.1 million for the three and nine months ended September 30, 2018 and $0 for all preceding periods. Stock-Based Compensation Cost The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three and nine months ended September 30, 2018 and 2017 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Stock options $ 2,316 $ 2,349 $ 7,558 $ 5,690 Vesting of restricted stock grants 6 540 1,007 1,620 Stock awarded to directors and officers — — — 4,400 Employee stock purchase plan 94 — 94 — Total stock-based compensation expense $ 2,416 $ 2,889 $ 8,659 $ 11,710 Cost of sales $ 64 $ 48 $ 164 $ 96 Research and development expenses 688 567 1,915 1,475 Selling, general, and administrative expenses 1,664 2,274 6,580 10,139 Total stock-based compensation expense $ 2,416 $ 2,889 $ 8,659 $ 11,710

Net Loss per Share Attributable

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Athenex, Inc. Common Stockholders	10. Net Loss per Share Attributable to Athenex, Inc. Common Stockholders Basic net loss per share is calculated by dividing net loss attributable to Athenex, Inc. common stockholders by the weighted-average number of common shares issued, outstanding, and vested during the period. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share and common shares equivalents for the period using the treasury-stock method. For the purposes of this calculation, warrants for common stock and stock options are considered common stock equivalents but are only included in the calculation of diluted net loss per share when their effect is dilutive. The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Stock options and other common stock equivalents 111,119,444 10,736,494 10,397,140 9,989,045 Unvested restricted shares 4,891 265,000 152,808 444,544 Total potential dilutive shares 111,124,335 11,001,494 10,549,948 10,433,589

Business Segment, Geographic, a

Business Segment, Geographic, and Concentration Risk Information	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Business Segment, Geographic, and Concentration Risk Information	11. Business Segment, Geographic, and Concentration Risk Information The Company has three operating segments, which are organized based mainly on the nature of the business activities performed and regulatory environments in which they operate. The Company also considers the types of products from which the reportable segments derive their revenue (only applicable to two reportable segments). Each operating segment has a segment manager who is held accountable for operations and has discrete financial information that is regularly reviewed by the Company’s chief operating decision-maker. The Company’s operating segments are as follows: Oncology Innovation Platform —This operating segment performs research and development on certain of the Company’s proprietary drugs, from the preclinical development of its chemical compounds, to the execution and analysis of its several clinical trials. This segment focuses specifically on the Orascovery oral absorption platform, the Src Kinase inhibitors, and the transmucosal drug delivery system. This segment performs research in the United States, Taiwan, Hong Kong, and mainland China. Global Supply Chain Platform —This operating segment includes Athenex Pharma Solutions and Polymed. Athenex Pharma Solutions is a contract manufacturing company that provides small to mid-scale Current Good Manufacturing Practices (“cGMP”) manufacturing of clinical and commercial products for pharmaceutical and biotech companies. Athenex Pharma Solutions also performs microbiological and analytical testing for raw material and formulated products and has expanded and begun to manufacture and sell pharmaceutical products under 503B regulations set forth by the U.S. Food and Drug Administration (“FDA”). Polymed markets and sells active pharmaceutical ingredient (“API”) and medical devices in North America, Europe, and Asia from its locations in Texas and China. Polymed also develops new compounds, processing techniques, and manufactures API at Taihao, a cGMP facility in Chongqing, China. Commercial Platform —This operating segment includes Athenex Pharmaceutical Division, which focuses on the manufacturing, distribution, and sales of specialty pharmaceuticals. This segment provides services and products to external customers based mainly in the United States. The Company’s Oncology Innovation Platform segment operates and holds long-lived assets located in the United States, Taiwan, Hong Kong, and mainland China. The Global Supply Chain Platform segment operates and holds long-lived assets located in the United States and China. The Commercial Platform segment operates and holds long-lived assets located in the United States. For geographic segment reporting, product sales have been attributed to countries based on the location of the customer. Segment information is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Net (loss) income attributable to Athenex, Inc.: Oncology Innovation Platform $ (37,639 ) $ (22,558 ) $ (65,985 ) $ (83,836 ) Global Supply Chain Platform (6,089 ) (1,564 ) (16,780 ) (4,693 ) Commercial Platform (2,443 ) 848 (7,562 ) (14,358 ) Total consolidated net loss attributable to Athenex, Inc. $ (46,171 ) $ (23,274 ) $ (90,327 ) $ (102,887 ) Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Total revenue: Oncology Innovation Platform $ 5,117 $ 205 $ 30,532 $ 1,208 Global Supply Chain Platform 7,092 8,601 17,991 19,407 Commercial Platform 7,315 7,378 23,006 9,274 Total revenue for reportable segments 19,524 16,184 71,529 29,889 Intersegment revenue (1,096 ) (2,190 ) (3,700 ) (6,719 ) Total consolidated revenue $ 18,428 $ 13,994 $ 67,829 $ 23,170 Intersegment revenue eliminated in the above table reflects sales from the Global Supply Chain Platform to the Oncology Innovation Platform. Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Total revenue by product group: API sales $ 3,690 $ 5,345 $ 9,538 $ 10,369 Medical device sales 1,322 562 2,342 1,128 Contract manufacturing revenue 17 250 412 934 Commercial product sales 8,280 7,505 25,092 9,547 License fees 5,000 — 30,000 500 Consulting revenue 96 60 278 256 Grant revenue 23 272 167 436 Total consolidated revenue $ 18,428 $ 13,994 $ 67,829 $ 23,170 Intersegment revenue is recorded by the selling segment when it is realized or realizable and all revenue recognition criteria are met. Upon consolidation, all intersegment revenue and related cost of sales are eliminated from the selling segment’s ledger. Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Total depreciation and amortization: Oncology Innovation Platform $ 174 $ 130 $ 505 $ 342 Global Supply Chain Platform 490 548 1,185 1,569 Commercial Platform 245 243 734 674 Total consolidated depreciation and amortization $ 909 $ 921 $ 2,424 $ 2,585 September 30, December 31, 2018 2017 Total assets: Oncology Innovation Platform $ 164,480 $ 65,966 Global Supply Chain Platform 51,327 51,128 Commercial Platform 28,660 23,319 Total consolidated assets $ 244,467 $ 140,413 Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Total revenue: United States $ 9,559 $ 8,114 $ 27,405 $ 11,056 Spain 5,000 — 30,000 — India 259 3,015 1,701 5,275 Austria 2,227 964 5,102 2,682 China 306 1,038 1,917 2,267 Other foreign countries 1,077 863 1,704 1,890 Total consolidated revenue $ 18,428 $ 13,994 $ 67,829 $ 23,170 September 30, December 31, 2018 2017 Total property and equipment, net: United States $ 6,458 $ 5,305 China 4,716 4,346 Total consolidated property and equipment, net $ 11,174 $ 9,651 Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment. Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Percentage of total revenue by customer: Customer A 27 % — % 44 % — % Customer B 13 % 5 % 9 % 4 % Customer C 12 % 16 % 13 % 11 % Customer D 11 % 5 % 8 % 3 % Customer E 10 % 7 % 6 % 11 % Customer F 1 % 18 % 2 % 20 % September 30, December 31, 2018 2017 Percentage of total accounts receivable by customer: Customer A 27 % 18 % Customer B 20 % 10 % Customer C 13 % 6 % Customer D 10 % 4 % Customer E — % 26 % Customer F — % 13 %

Revenue Recognition

Revenue Recognition	9 Months Ended
	Sep. 30, 2018
Revenue From Contract With Customer [Abstract]
Revenue Recognition	12. Revenue Recognition The Company records revenue in accordance with ASC, Topic 606 “ Revenue from Contracts with Customers .” Under Topic 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of Topic 606, the entity performs the following five steps: (i) identifies the contract(s) with a customer; (ii) identifies the performance obligations in the contract; (iii) determines the transaction price; (iv) allocates the transaction price to the performance obligations in the contract; and (v) recognizes revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Following is a description of principal activities – separated by reportable segments – from which the Company generates its revenue (See Note 11 – Business Segment, Geographic, and Concentration Risk Information ). 1. Oncology Innovation Platform License fees and consulting revenue The Company out-licenses certain of its intellectual property (“IP”) and provides related consulting services to pharmaceutical companies in specific territories that allow the customer to use, develop, commercialize, or otherwise exploit the licensed IP. In accordance with Topic 606, the Company analyzes each of its out-licensing contracts with customers to identify each of the performance obligations within the contract. Each out-license contains multiple performance obligations. The Company has determined that each of its out-license agreements with customers are classified as functional licenses and are capable of being distinct, because the IP that is licensed carries standalone value and is not expected to be altered through the life of the agreement. Therefore, for each of its out-licensing agreements, the Company has determined that the execution of the license and delivery of the IP to the licensee is a distinct performance obligation. As such, the Company records revenue at a point-in-time for its out-licensing if any of the transaction price is allocated to the obligation, including up-front licensing fee payments. The Company’s classification of each out-licensing as such requires significant judgment to be used by management. The Company considers the economic and regulatory characteristics of the licensed IP to determine if it has standalone value on the date of the licensing, which would make the licensing distinct and dictate that the Company recognizes any transaction price allocated to the license performance obligation at a point-in-time. Revenue recognized at a point-in-time for the execution of a distinct licensing of IP amounted to $5.0 million and $0 for the three months ended September 30, 2018 and 2017, respectively, and $30.0 million and $0 for the nine months ended September 30, 2018 and 2017, respectively. Other performance obligations included in the Company’s out-licensing agreements include reaching milestone development and regulatory events by performing research and development activities over the licensed IP. The Company did not reach any milestone events during the nine months ended September 30, 2018 and reached one milestone event during the nine months ended September 30, 2017 resulting in $0.5 million of revenue recognized. The Company recorded the associated milestone payment as revenue at a point-in-time. Certain out-licensing agreements include performance obligations to manufacture and provide drug product in the future when the licensed product is approved for commercial sale. To date, the Company has not satisfied any of these performance obligations as none of its drugs have been approved by the regulatory agencies in each of the licensed territories. In addition to the multiple performance obligations, the Company’s out-licensing agreements include variable pricing. After the performance obligations are identified, the Company determines each portion of the transaction price, which generally includes upfront fees, milestone payments, and royalty payments. The Company begins by allocating the payments set forth in the agreement to the performance obligation to which the consideration is related. Then, the Company considers whether or not that transaction price is fixed, variable, or subject to return. If any portion of the transaction price is constrained by more than one performance obligation, the Company allocated that portion of the transaction price to the performance obligation that will be satisfied later and will not recognize revenue until it is fully satisfied and the constraint on the transaction price no longer exists. There are no other significant methods employed to allocate the transaction price to performance obligations in a contract. The Company exercises significant judgment when allocating the variable transaction prices to the proper performance obligations, considering if any of those payments are refundable or are contingent on any future events. Grant revenue The Company receives grant award funding to support its continuing research and development efforts. The Company considers these grants to be operating revenue as they support the Company’s primary operating activities. Revenue is recognized when the underlying performance obligation is satisfied, which is generally when all grant eligibility criteria are met at a point-in-time. Performance obligations in these contracts include various eligibility conditions that the Company must satisfy to maintain the grant agreement. Grant revenue is not significant to the consolidated financial statements. Performance obligations remaining as of September 30, 2018 were not material to the financial statements and do not significantly alter the Company’s business operations. Contracts for the grant revenue include a fixed transaction price and a single performance obligation. Therefore, the transaction price is allocated to the single obligation and there are no further allocation methods or assumptions used. 2. Global Supply Chain Platform The Company’s Global Supply Chain Platform manufactures API for use internally in its research and development and clinical studies and for sale to pharmaceutical customers globally. API revenue earned by the Global Supply Platform is recognized when the Company has satisfied its performance obligation, which is the shipment or the delivery of drug products. The underlying contracts for these sales are generally purchase orders and the Company recognizes revenue at a point-in-time. Any remaining performance obligations related to product sales are the result of customer deposits and are reflected in the deferred revenue contract liability balance. The Company also generates revenue, to a lesser extent, by providing small to mid-scale cGMP manufacturing of clinical and commercial products for pharmaceutical and biotech companies and selling pharmaceutical products under 503B regulations set forth by the FDA. 3. Commercial Platform The Company’s Commercial Platform generates revenue by distributing specialty products through independent pharmaceutical wholesalers. The wholesalers then sell to an end-user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously established by the end-user and the Company. Sales are initially recorded at the list price sold to the wholesaler. Because these prices will be reduced for the end-user, the Company records a contra asset in accounts receivable and a reduction to revenue at the time of the sale, using the difference between the list price and the estimated end-user contract price. Upon the sale by the wholesaler to the end-user, the wholesaler will chargeback the difference between the original list price and price at which the product was sold to the end-user and such chargeback is offset against the initial estimated contra asset. The significant estimates inherent in the initial chargeback provision relate to wholesale units pending chargeback and to the ultimate end-user contract selling price. The Company bases the estimate for these factors on product-specific sales and internal chargeback processing experience, as well as estimated wholesaler inventory stocking levels. As of September 30, 2018 and December 31, 2017, the Company’s total provision for chargebacks and other deductions totaled $13.2 million and $3.7 million, respectively, included as a reduction of accounts receivable. The Company offers cash discounts, which approximate 2.0% of the gross sales price, as an incentive for prompt customer payment, and, consistent with industry practice, the Company’s return policy permits customers to return products within a window of time before and after the expiration of product dating. The Company expects that its wholesale customers will make prompt payments to take advantage of the cash discounts, and expects customers to use their right of return. Therefore, at the time of sale, product revenue and accounts receivable are reduced by the full amount of the discount offered and the return expected. The Company considers payment performance and historical return rates and adjusts the accrual to reflect actual experience. As of September 30, 2018 and December 31, 2017, the Company’s accrual for cash discounts and return accrual included as a reduction of accounts receivable were not material to the consolidated financial statements. The Company also offers contractual allowances, generally rebates or administrative fees, to certain wholesale customers, group purchasing organizations (“GPOs”), and end-user customers, consistent with pharmaceutical industry practices. Settlement of rebates and fees may generally occur from one to five months from date of sale. The Company provides a provision for contractual allowances at the time of sale based on the historical relationship between sales and such allowances. Contractual allowances are reflected in the consolidated financial statements as a reduction of revenue and accounts receivable or as accrued expenses. The Company exercises significant judgment in its estimates of the variable transaction price at the time of the sale and recognizes revenue when the performance obligation is satisfied. Factors that determine the final net transaction price include chargebacks, fees for service, cash discounts, rebates, returns, warranties, and other factors. The Company estimates all of these variables based on historical data obtained from previous sales finalized with the end-user customer on a product-by-product basis. At the time of sale, revenue is recorded net of each of these deductions. Through the normal course of business, the wholesaler will sell the product to the end-user, determining the actual chargeback, return products, and take advantage of cash discounts, charge fees for services, and claim warranties on products. The final transaction price per product is compared to the initial estimated net sale price and reviewed for accuracy. The final prices and other factors are immediately included in the Company’s historical data from which it will estimate the transaction price for future sales. The underlying contracts for these sales are generally purchase orders including a single performance obligation, generally the shipment or delivery of products and the Company recognizes this revenue at a point-in-time. Disaggregation of revenue The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer. For the Three Months Ended September 30, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 2,244 $ 7,315 $ 9,559 Spain 5,000 — — 5,000 India — 258 — 258 Austria — 2,227 — 2,227 China 117 189 — 306 Other foreign countries — 1,077 — 1,077 Total revenue $ 5,117 $ 5,996 $ 7,315 $ 18,428 For the Three Months Ended September 30, 2017 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 736 $ 7,378 $ 8,114 India — 3,015 — 3,015 Austria — 964 — 964 China 205 833 — 1,038 Other foreign countries — 863 — 863 Total revenue $ 205 $ 6,411 $ 7,378 $ 13,994 For the Nine Months Ended September 30, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 4,399 $ 23,006 $ 27,405 Spain 30,000 — — 30,000 India — 1,701 — 1,701 Austria — 5,102 — 5,102 China 532 1,385 — 1,917 Other foreign countries — 1,704 — 1,704 Total revenue $ 30,532 $ 14,291 $ 23,006 $ 67,829 For the Nine Months Ended September 30, 2017 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 1,781 $ 9,274 $ 11,055 India — 5,275 — 5,275 Austria — 2,682 — 2,682 China 708 1,058 — 1,766 Other foreign countries 500 1,892 — 2,392 Total revenue $ 1,208 $ 12,688 $ 9,274 $ 23,170 The Company also disaggregates its revenue by product group which can be found in Note 11 – Business Segment, Geographic, and Concentration Risk Information Contract balances The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers. September 30, 2018 December 31, 2017 (In Thousands) Accounts receivable, gross $ 20,252 $ 12,263 Chargebacks and other deductions (13,154 ) (3,711 ) Allowance for doubtful accounts (27 ) (84 ) Accounts receivable, net $ 7,071 $ 8,468 Deferred revenue $ 364 $ 1,202 Total contract liabilities $ 364 $ 1,202 The following tables illustrate accounts receivable balances by reportable segments. September 30, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ 9 $ 3,369 $ 16,874 $ 20,252 Chargebacks and other deductions — — (13,154 ) (13,154 ) Allowance for doubtful accounts — (27 ) — (27 ) Accounts receivable, net $ 9 $ 3,342 $ 3,720 $ 7,071 December 31, 2017 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ 49 $ 4,553 $ 7,661 $ 12,263 Allowance for doubtful accounts, chargebacks, and other deductions — (84 ) (3,711 ) (3,795 ) Accounts receivable, net $ 49 $ 4,469 $ 3,950 $ 8,468 As of September 30, 2018, $0.4 million of the deferred revenue balance relates to customer deposits made by customers of the Global Supply Chain Platform. As of December 31, 2017, the $1.2 million contract liability related to customer deposits made by customers of the Global Supply Chain Platform. The Company satisfied its performance obligations allocated to these contract liabilities during the nine months ended September 30, 2018. There were no other material changes to contract balances during the nine months ended September 30, 2018. Practical expedients used During the adoption of ASC 606, the Company applied the practical expedient in paragraph 606-10-10-4, the Portfolio Approach The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations related to the license of intellectual property (“IP”). This practical expedient is applied because the out-licensing agreements include sales-based royalties in exchange for the license of IP accounted for in accordance with Topic 606 and there is significant uncertainty surrounding the future variable consideration that could be received.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Future minimum payments under the non-cancelable operating leases consisted of the following as of September 30, 2018(in thousands): Year ending December 31: Minimum payments 2018 (remaining three months) $ 712 2019 2,383 2020 2,247 2021 1,844 2022 1,802 Thereafter 4,672 $ 13,660 Legal Proceedings From time to time, the Company is subject to claims and litigation arising in the ordinary course of business. These claims may include assertions that the Company’s products infringe existing patents and claims that the use of its products has caused personal injuries. The Company intends to vigorously defend any such litigation that may arise under all defenses that would be available. Vasopressin (Generic version of Vasostrict®) On August 13, 2018, Athenex Pharma Solutions and Athenex Pharmaceutical Division, LLC, wholly-owned subsidiaries of the Company, filed a complaint for declaratory judgment against Par Pharmaceuticals, Inc., Par Sterile Products, LLC and Endo Par Innovation Company, LLC (together, “Par”) in the United States District Court for the Western District of New York (the “Court”). The Company is seeking a declaratory judgment from the Court that the Company’s compounded Vasopressin drug products in ready-to-use form do not infringe on patents that Par has with respect to its Vasostrict® product and that Par’s patents are invalid. On October 22, 2018, Par filed a motion to dismiss the complaint on the basis that the Court does not have subject matter jurisdiction and that motion is currently pending. In addition, on August 13, 2018, Athenex Pharma Solutions, LLC and Athenex Pharmaceutical Division, LLC filed a motion to intervene and seek the dismissal of Par’s complaint against the FDA and certain governmental officials in the United States District Court for the District of Columbia. Par has sought declaratory and injunctive relief against the FDA and certain governmental officials that: (i) Vasopressin be delisted from Category 1 of the FDA’s list of bulk drug substances under evaluation pursuant to Section 503B of the Federal Food, Drug and Cosmetic Act (“FDCA”), (ii) the expansion of the FDA’s enforcement discretion to Category 1 substances, be enjoined; and (iii) that the FDA be enjoined from authorizing the compounding of Vasopressin under Section 503B of the FDCA. Athenex’s motion to intervene was granted. Par filed a preliminary injunction motion and Athenex and the FDA filed motions for judgment on the pleadings. Prior to hearing those motions, the Court issued an order staying the litigation until the earlier of December 31, 2018 or when the FDA issues its final clinical need determination for Vasopressin. On August 14, 2018, the Company began selling compounded Vasopressin Injection in ready-to-use premix IV bags. The Company has sold and will continue to sell these products. Therefore, an adverse final determination that the patent is valid and infringed could have a material adverse effect on the Company’s business, results of operations, financial condition and cash flows.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with GAAP. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments ) considered necessary for a fair presentation of the results of the Company for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been fully eliminated in consolidation. Results of the operations for the three and nine months ended September 30, 2018 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. These financial statements should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on March 26, 2018.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in clinical research accruals, chargebacks, allowance for doubtful accounts, inventory reserves, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates.
Concentration of Credit Risk, Other Risks and Uncertainties	Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company deposits its cash equivalents in interest-bearing money market accounts and invests in highly liquid U.S. treasury notes, commercial papers and corporate bonds. The Company deposits its cash with multiple financial institutions. Cash balances exceed federally insured limits. The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any one corporate issuer and establishing a minimum allowable credit rating. The Company also has significant assets and liabilities held in its overseas manufacturing facility in China, and therefore is subject to foreign currency fluctuation.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted In February 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-02, “ Leases (Topic 842) Commitments and Contingencies In June 2018, the FASB issued ASU No. 2018-07, “ Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,” Compensation – Stock Compensation,”
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) No. 2014-09, “ Revenue from Contracts with Customers (Topic 606) Revenue Recognition In November 2016, the FASB issued ASU 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash In May 2017, the FASB issued ASU 2017-09, “ Stock Compensation—Scope of Modification Accounting

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2018
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following (in thousands): September 30, 2018 December 31, 2017 Raw materials and purchased parts $ 2,778 $ 1,471 Work in progress 3,303 1,877 Finished goods 19,150 13,213 Total inventories $ 25,231 $ 16,561

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	9 Months Ended
	Sep. 30, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Identifiable Intangible Asset, Net	The Company’s identifiable intangible assets, net, consist of the following (in thousands): September 30, 2018 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 4,650 $ 1,836 $ — $ 2,814 Polymed customer list 1,593 873 — 720 Polymed technology 3,712 930 — 2,782 Product rights 530 231 — 299 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,026 — — 1,026 Effect of currency translation adjustment (387 ) — — (387 ) Total intangible assets, net $ 11,124 $ 3,870 $ - $ 7,254 December 31, 2017 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets Licenses $ 4,650 $ 1,173 $ — $ 3,477 Polymed customer list 1,593 675 — 918 Polymed technology 3,712 762 — 2,950 Product rights 530 132 — 398 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,106 — 80 1,026 Effect of currency translation adjustment (197 ) — — (197 ) Total intangibles, net $ 11,394 $ 2,742 $ 80 $ 8,572

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at September 30, 2018 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 5,028 $ 5,028 $ — $ — Short-term investments - commercial paper 45,064 — 45,064 — Short-term investments - corporate notes 18,126 — 18,126 — Short-term investments - U.S. government bonds 32,141 — 32,141 — Investment 399 399 — — Total assets $ 100,758 $ 5,427 $ 95,331 $ — Fair Value Measurements at December 31, 2017 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 13,804 $ 13,804 $ — $ — Short-term investments - commercial paper 14,982 — 14,982 — Short-term investments - corporate notes 2,824 — 2,824 — Short-term investments - U.S. government bonds 5,006 — 5,006 — Investment 328 328 — — Total assets $ 36,944 $ 14,132 $ 22,812 $ —

Stock Based Compensation (Table

Stock Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Option Activity	The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (in thousands, except stock option amounts and exercise price ): Stock Options Weighted- Average Exercise price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2017 10,176,643 $ 7.19 6.83 $ 88,615 Granted 1,411,650 17.25 Exercised (607,655 ) 5.59 Forfeited and expired (194,135 ) 10.77 Outstanding at September 30, 2018 10,786,503 $ 8.53 6.64 $ 75,562 Vested and exercisable at September 30, 2018 7,808,020 $ 6.51 5.80 $ 70,511
Schedule of Weighted Average Assumptions Used as Inputs to Black-Scholes Model	The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated: Nine Months Ended Nine Months Ended September 30, 2018 September 30, 2017 Weighted average grant date fair value $ 9.87 $ 6.90 Expected dividend yield — % — % Expected stock price volatility 59 % 66 % Risk-free interest rate 2.60 % 1.74 % Expected life of options (in years) 6.1 6.2
Schedule of Stock-Based Compensation Expense	The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three and nine months ended September 30, 2018 and 2017 (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Stock options $ 2,316 $ 2,349 $ 7,558 $ 5,690 Vesting of restricted stock grants 6 540 1,007 1,620 Stock awarded to directors and officers — — — 4,400 Employee stock purchase plan 94 — 94 — Total stock-based compensation expense $ 2,416 $ 2,889 $ 8,659 $ 11,710 Cost of sales $ 64 $ 48 $ 164 $ 96 Research and development expenses 688 567 1,915 1,475 Selling, general, and administrative expenses 1,664 2,274 6,580 10,139 Total stock-based compensation expense $ 2,416 $ 2,889 $ 8,659 $ 11,710

Net Loss per Share Attributab_2

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders (Tables)	9 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Schedule Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Stock options and other common stock equivalents 111,119,444 10,736,494 10,397,140 9,989,045 Unvested restricted shares 4,891 265,000 152,808 444,544 Total potential dilutive shares 111,124,335 11,001,494 10,549,948 10,433,589

Business Segment, Geographic,_2

Business Segment, Geographic, and Concentration Risk Information (Tables)	9 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Summary of Segment Information	Segment information is as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Net (loss) income attributable to Athenex, Inc.: Oncology Innovation Platform $ (37,639 ) $ (22,558 ) $ (65,985 ) $ (83,836 ) Global Supply Chain Platform (6,089 ) (1,564 ) (16,780 ) (4,693 ) Commercial Platform (2,443 ) 848 (7,562 ) (14,358 ) Total consolidated net loss attributable to Athenex, Inc. $ (46,171 ) $ (23,274 ) $ (90,327 ) $ (102,887 )
Summary of Revenue by Segments	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Total revenue: Oncology Innovation Platform $ 5,117 $ 205 $ 30,532 $ 1,208 Global Supply Chain Platform 7,092 8,601 17,991 19,407 Commercial Platform 7,315 7,378 23,006 9,274 Total revenue for reportable segments 19,524 16,184 71,529 29,889 Intersegment revenue (1,096 ) (2,190 ) (3,700 ) (6,719 ) Total consolidated revenue $ 18,428 $ 13,994 $ 67,829 $ 23,170
Summary of Revenue by Product Group	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Total revenue by product group: API sales $ 3,690 $ 5,345 $ 9,538 $ 10,369 Medical device sales 1,322 562 2,342 1,128 Contract manufacturing revenue 17 250 412 934 Commercial product sales 8,280 7,505 25,092 9,547 License fees 5,000 — 30,000 500 Consulting revenue 96 60 278 256 Grant revenue 23 272 167 436 Total consolidated revenue $ 18,428 $ 13,994 $ 67,829 $ 23,170
Summary of Depreciation, Amortization and Assets by Segment	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Total depreciation and amortization: Oncology Innovation Platform $ 174 $ 130 $ 505 $ 342 Global Supply Chain Platform 490 548 1,185 1,569 Commercial Platform 245 243 734 674 Total consolidated depreciation and amortization $ 909 $ 921 $ 2,424 $ 2,585 September 30, December 31, 2018 2017 Total assets: Oncology Innovation Platform $ 164,480 $ 65,966 Global Supply Chain Platform 51,327 51,128 Commercial Platform 28,660 23,319 Total consolidated assets $ 244,467 $ 140,413
Summary of Revenue by Geographical Segment	Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Total revenue: United States $ 9,559 $ 8,114 $ 27,405 $ 11,056 Spain 5,000 — 30,000 — India 259 3,015 1,701 5,275 Austria 2,227 964 5,102 2,682 China 306 1,038 1,917 2,267 Other foreign countries 1,077 863 1,704 1,890 Total consolidated revenue $ 18,428 $ 13,994 $ 67,829 $ 23,170
Summary of Property and Equipment by Geographical Segment	September 30, December 31, 2018 2017 Total property and equipment, net: United States $ 6,458 $ 5,305 China 4,716 4,346 Total consolidated property and equipment, net $ 11,174 $ 9,651
Summary of Customer Revenue and Accounts Receivable Concentration	Customer revenue and accounts receivable concentration amounted to the following for the identified periods. These customers relate to the Commercial Platform segment and the Global Supply Chain Platform segment. Three Months Ended September 30, Nine Months Ended September 30, 2018 2017 2018 2017 Percentage of total revenue by customer: Customer A 27 % — % 44 % — % Customer B 13 % 5 % 9 % 4 % Customer C 12 % 16 % 13 % 11 % Customer D 11 % 5 % 8 % 3 % Customer E 10 % 7 % 6 % 11 % Customer F 1 % 18 % 2 % 20 % September 30, December 31, 2018 2017 Percentage of total accounts receivable by customer: Customer A 27 % 18 % Customer B 20 % 10 % Customer C 13 % 6 % Customer D 10 % 4 % Customer E — % 26 % Customer F — % 13 %

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Sep. 30, 2018
Revenue From Contract With Customer [Abstract]
Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer	Disaggregation of revenue The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer. For the Three Months Ended September 30, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 2,244 $ 7,315 $ 9,559 Spain 5,000 — — 5,000 India — 258 — 258 Austria — 2,227 — 2,227 China 117 189 — 306 Other foreign countries — 1,077 — 1,077 Total revenue $ 5,117 $ 5,996 $ 7,315 $ 18,428 For the Three Months Ended September 30, 2017 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 736 $ 7,378 $ 8,114 India — 3,015 — 3,015 Austria — 964 — 964 China 205 833 — 1,038 Other foreign countries — 863 — 863 Total revenue $ 205 $ 6,411 $ 7,378 $ 13,994 For the Nine Months Ended September 30, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 4,399 $ 23,006 $ 27,405 Spain 30,000 — — 30,000 India — 1,701 — 1,701 Austria — 5,102 — 5,102 China 532 1,385 — 1,917 Other foreign countries — 1,704 — 1,704 Total revenue $ 30,532 $ 14,291 $ 23,006 $ 67,829 For the Nine Months Ended September 30, 2017 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total United States $ — $ 1,781 $ 9,274 $ 11,055 India — 5,275 — 5,275 Austria — 2,682 — 2,682 China 708 1,058 — 1,766 Other foreign countries 500 1,892 — 2,392 Total revenue $ 1,208 $ 12,688 $ 9,274 $ 23,170
Summary of Receivables and Contract Liabilities From Contracts with Customers	The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers. September 30, 2018 December 31, 2017 (In Thousands) Accounts receivable, gross $ 20,252 $ 12,263 Chargebacks and other deductions (13,154 ) (3,711 ) Allowance for doubtful accounts (27 ) (84 ) Accounts receivable, net $ 7,071 $ 8,468 Deferred revenue $ 364 $ 1,202 Total contract liabilities $ 364 $ 1,202
Summary of Accounts Receivable Balances by Reportable Segments	The following tables illustrate accounts receivable balances by reportable segments. September 30, 2018 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ 9 $ 3,369 $ 16,874 $ 20,252 Chargebacks and other deductions — — (13,154 ) (13,154 ) Allowance for doubtful accounts — (27 ) — (27 ) Accounts receivable, net $ 9 $ 3,342 $ 3,720 $ 7,071 December 31, 2017 (In Thousands) Oncology Innovation Platform Global Supply Chain Platform Commercial Platform Consolidated Total Accounts receivable, gross $ 49 $ 4,553 $ 7,661 $ 12,263 Allowance for doubtful accounts, chargebacks, and other deductions — (84 ) (3,711 ) (3,795 ) Accounts receivable, net $ 49 $ 4,469 $ 3,950 $ 8,468

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments Under Non-Cancelable Leases	Future minimum payments under the non-cancelable operating leases consisted of the following as of September 30, 2018(in thousands): Year ending December 31: Minimum payments 2018 (remaining three months) $ 712 2019 2,383 2020 2,247 2021 1,844 2022 1,802 Thereafter 4,672 $ 13,660

Company and Nature of Business

Company and Nature of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jul. 03, 2018	Feb. 28, 2018	Jan. 31, 2018	Sep. 30, 2017	Jun. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Subsidiary Or Equity Method Investee [Line Items]
Common stock, shares issued						68,561,678		59,894,362
Sale of common stock						$ 117,148	$ 64,194
Accumulated deficit						$ 416,603		$ 326,276
Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Warrants to purchase common stock outstanding	425,000
Warrants to purchase common stock, share price	$ 18.66
Perceptive | Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Common stock share price	$ 18.66
Number of shares issued and sold	2,679,528
Gross proceeds from debt and equity financing	$ 100,000
Aggregate net proceeds of debt and equity financing, net of fees and offering expenses	97,100
Sale of common stock	50,000
Senior Secured Loan | Perceptive | Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Convertible bonds, aggregate principal value	$ 50,000
Debt instrument maturity term	5 years
LIBOR | Senior Secured Loan | Perceptive | Private Financing Transactions
Subsidiary Or Equity Method Investee [Line Items]
Debt variable rate basis floor	2.00%
Basis spread on variable rate	9.00%
Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Convertible bonds, aggregate principal value				$ 7,000	$ 68,000		$ 7,000
Convertible bonds, carrying value					55,800
Common stock discount rate				20.00%
Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Aggregate cash proceeds net of underwriting discounts and commissions and offering costs					64,200
Underwriting discounts and commissions					6,100
Offering costs					$ 5,600
Number of shares issued and sold						7,444,528	6,900,000
Sale of common stock						$ 7	$ 7
Common Stock | Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Shares issued upon conversion				795,455	7,727,273
IPO
Subsidiary Or Equity Method Investee [Line Items]
Common stock, shares issued					6,900,000
IPO | Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Common stock share price					$ 11
Underwriters
Subsidiary Or Equity Method Investee [Line Items]
Common stock share price		$ 15.25	$ 15.25
Number of shares issued and sold			4,300,000
Number of days granted to underwriters option to purchase additional shares			30 days
Number of additional common stock shares purchase		465,000	645,000
Net proceeds from stock issuance		$ 68,100
Underwriting discounts and commissions and offering expenses		$ 4,600

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials and purchased parts	$ 2,778	$ 1,471
Work in progress	3,303	1,877
Finished goods	19,150	13,213
Total inventories	$ 25,231	$ 16,561

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Identifiable Intangible Asset, Net (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Accumulated Amortization	$ 3,870	$ 2,742
Intangible asset, Effect of currency translation adjustment	(387)	(197)
Intangible assets Cost/Fair Value	11,124	11,394
Intangible assets Impairments		80
Intangible assets, net	7,254	8,572
CDE In- Process Research and Development
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost/Fair Value	1,026	1,106
Indefinite-lived intangible asset, Impairments		80
Indefinite-lived intangible asset, Net	1,026	1,026
Licensing Agreements
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	4,650	4,650
Finite-lived intangible asset, Accumulated Amortization	1,836	1,173
Finite-lived intangible asset, Net	2,814	3,477
Polymed Customer List
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	1,593	1,593
Finite-lived intangible asset, Accumulated Amortization	873	675
Finite-lived intangible asset, Net	720	918
Polymed Technology
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	3,712	3,712
Finite-lived intangible asset, Accumulated Amortization	930	762
Finite-lived intangible asset, Net	2,782	2,950
Product Rights
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	530	530
Finite-lived intangible asset, Accumulated Amortization	231	132
Finite-lived intangible asset, Net	$ 299	$ 398

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments					$ 80
Weighted-average useful life of intangible assets			8 years 9 months 7 days
Amortization expense of intangible assets	$ 400	$ 400	$ 1,200	$ 1,200
Research and Development Expenses
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments			0	$ 100
Licensing Agreements | Hanmi Pharmaceuticals Co. Ltd.
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 400
Acquired finite-lived intangible assets, amortization period			12 years 9 months
Licensing Agreements | Gland Pharma Limited
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 4,300
Customer List | Athenex Pharma Solutions
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period			7 years
Customer List | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period			6 years
Polymed Technology | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period			12 years

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assets, Level 1 to Level 2 transfers	$ 0	$ 0
Fair value assets, Level 2 to Level 1 transfers	0	0
Fair value liabilities, Level 1 to Level 2 transfers	0	0
Fair value liabilities, Level 2 to Level 1 transfers	0	0
Fair value assets, transfers into Level 3	0	0
Fair value assets, transfers out of Level 3	0	0
Fair value liabilities, transfers into Level 3	0	0
Fair value liabilities, transfers out of Level 3	$ 0	$ 0
Pharma Essentia | OTC | Taiwan | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of shares owned by company	68,000	68,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Assets:
Total assets	$ 100,758	$ 36,944
Money Market Funds
Assets:
Total assets	5,028	13,804
Short-term Investments - Commercial Paper
Assets:
Total assets	45,064	14,982
Short-term Investments - Corporate Notes
Assets:
Total assets	18,126	2,824
Short-term investments - U.S. Government Bonds
Assets:
Total assets	32,141	5,006
Investment
Assets:
Total assets	399	328
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total assets	5,427	14,132
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds
Assets:
Total assets	5,028	13,804
Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment
Assets:
Total assets	399	328
Significant Other Observable Inputs (Level 2)
Assets:
Total assets	95,331	22,812
Significant Other Observable Inputs (Level 2) | Short-term Investments - Commercial Paper
Assets:
Total assets	45,064	14,982
Significant Other Observable Inputs (Level 2) | Short-term Investments - Corporate Notes
Assets:
Total assets	18,126	2,824
Significant Other Observable Inputs (Level 2) | Short-term investments - U.S. Government Bonds
Assets:
Total assets	$ 32,141	$ 5,006

Asset Acquisition - Additional

Asset Acquisition - Additional Information (Details) - Axis Therapeutics - USD ($) $ in Millions	Jun. 29, 2018	Sep. 30, 2018
Asset Acquisition [Line Items]
Capital contributions to joint venture	$ 30	$ 30
Percentage of ownership in joint venture	55.00%
Research and Development Expenses
Asset Acquisition [Line Items]
Non-cash expense		$ 24.5
Licensing Agreements
Asset Acquisition [Line Items]
Upfront payment in the form of issuance of common stock, shares	267,952
Upfront payment in the form of issuance of common stock	$ 5
XLifeSc | IPR & D
Asset Acquisition [Line Items]
Percentage of ownership in joint venture	45.00%
Percentage of nonmonetary exchange of shares		45.00%
Fair value of equity shares issued		$ 24.5

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Tax [Line Items]
Income tax benefit	$ (30,000)	$ 11,000	$ (286,000)	$ (52,000)
Federal Income Tax [Member]
Income Tax [Line Items]
Income tax benefit			$ 0

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Jun. 30, 2018Agreement	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Sep. 30, 2018USD ($)ExecutiveRelatedParty$ / sharesshares	Sep. 30, 2017USD ($)shares	Dec. 31, 2017shares	Jun. 30, 2017shares
Related Party Transaction [Line Items]
Percentage of outstanding common stock holding				5.00%
Convertible Bonds
Related Party Transaction [Line Items]
Amounts owed to related party				$ 4,000,000
Number of related parties received convertible bonds | RelatedParty					2
Amount purchased in convertible bonds by holders of outstanding common stock and a director				$ 2,000,000
Bonds converted into shares of common stock | shares								2,727,273
Common Stock
Related Party Transaction [Line Items]
Sale of common stock, shares | shares					7,444,528	6,900,000
Avalon BioMedical
Related Party Transaction [Line Items]
Common stock shares held by related parties | shares		786,061			786,061		678,880
Percentage of common stock issued shares					1.00%		1.00%
Avalon BioMedical | In-licensing Agreement
Related Party Transaction [Line Items]
Number of in-licensing agreements | Agreement	2
Payment of upfront fees					$ 5,500,000
Payment of upfront fees in cash					3,500,000
Payment of upfront fees in equity					$ 2,000,000
Avalon BioMedical | Common Stock | In-licensing Agreement
Related Party Transaction [Line Items]
Sale of common stock, shares | shares					107,181
Common stock share price | $ / shares		$ 18.66			$ 18.66
Pharma Essentia
Related Party Transaction [Line Items]
Licenses revenue		$ 0	$ 0		$ 300,000	$ 500,000
Executive Officer
Related Party Transaction [Line Items]
Number of executives | Executive					1
ZenRx
Related Party Transaction [Line Items]
Licenses revenue		0	0		$ 0	0
ZenRx | Clinical Development Services
Related Party Transaction [Line Items]
Payments to related party for services received		100,000	200,000		300,000	500,000
RSJ Consulting LLC
Related Party Transaction [Line Items]
Consulting services incurred		$ 0			$ 0	$ 100,000
RSJ Consulting LLC | Maximum
Related Party Transaction [Line Items]
Consulting services incurred			$ 100,000

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 2,416,000	$ 2,889,000	$ 8,659,000	$ 11,710,000
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	2,316,000	2,349,000	7,558,000	5,690,000
Unrecognized compensation cost related to non-vested stock options expected to be recognized	20,000,000		$ 20,000,000
Unrecognized compensation expense related to non-vested stock options, weighted-average period of recognition			1 year 10 months 24 days
Total intrinsic value of stock options exercised			$ 6,500,000	1,600,000
Restricted Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 6,000	540,000	$ 1,007,000	1,620,000
Restricted shares vested			240,000
Restricted shares remain unvested	0		0
2013, 2007 and 2004 Plans | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock options authorized grant	11,800,000		11,800,000
2017 Plans
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	5,200,000		5,200,000
Shares issued			0
2017 Plans | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock reserved for future issuance	1,000,000		1,000,000
Stock-based compensation expense	$ 100,000	$ 0	$ 100,000	$ 0
Percentage of discount on purchase price of common stock			15.00%
Employee stock purchase plan, description			Under the ESPP, shares of the Company’s common stock may be purchased at a discount (15%) of the lesser of the closing price of the Company’s common stock on the first trading or the last trading day of the offering period. The current offering period extends from July 1, 2018 to November 30, 2018. The Company expects to offer 6-month offering periods after the current period.

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Stock Options
Stock Options, Outstanding Beginning Balance	10,176,643
Stock Options, Granted	1,411,650
Stock Options, Exercised	(607,655)
Stock Options, Forfeited and expired	(194,135)
Stock Options, Outstanding Ending Balance	10,786,503	10,176,643
Stock Options, Vested and exercisable	7,808,020
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 7.19
Weighted Average Exercise Price, Granted	17.25
Weighted Average Exercise Price, Exercised	5.59
Weighted Average Exercise Price, Forfeited and expired	10.77
Weighted Average Exercise Price, Outstanding Ending Balance	8.53	$ 7.19
Weighted Average Exercise Price, Vested and exercisable	$ 6.51
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term, Outstanding	6 years 7 months 20 days	6 years 9 months 29 days
Weighted Average Remaining Contractual Term, Vested and exercisable	5 years 9 months 18 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding	$ 75,562	$ 88,615
Aggregate Intrinsic Value, Vested and exercisable	$ 70,511

Stock Based Compensation - Sc_2

Stock Based Compensation - Schedule of Weighted Average Assumptions Used as Inputs to Black-Scholes Option Pricing Model (Detail) - $ / shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant date fair value	$ 9.87	$ 6.90
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	59.00%	66.00%
Risk-free interest rate	2.60%	1.74%
Expected life of options (in years)	6 years 1 month 6 days	6 years 2 months 12 days

Stock Based Compensation - Sc_3

Stock Based Compensation - Schedule of Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 2,416	$ 2,889	$ 8,659	$ 11,710
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	2,316	2,349	7,558	5,690
Vesting of Restricted Stock Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	6	540	1,007	1,620
Stock Awarded to Directors and Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized				4,400
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	94		94
Cost of Sales
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	64	48	164	96
Research and Development Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	688	567	1,915	1,475
Selling, General, and Administrative Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 1,664	$ 2,274	$ 6,580	$ 10,139

Net Loss per Share Attributab_3

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders - Schedule Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive common shares	111,124,335	11,001,494	10,549,948	10,433,589
Stock Options and Other Common Stock Equivalents
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive common shares	111,119,444	10,736,494	10,397,140	9,989,045
Unvested Restricted Common Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive common shares	4,891	265,000	152,808	444,544

Business Segment, Geographic,_3

Business Segment, Geographic, and Concentration Risk Information - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2018Segment
Segment Reporting Information [Line Items]
Number of operating segments	3
Segments Deriving Revenue
Segment Reporting Information [Line Items]
Number of reportable segments	2

Business Segment, Geographic,_4

Business Segment, Geographic, and Concentration Risk Information - Summary of Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (46,171)	$ (23,274)	$ (90,327)	$ (102,887)
Oncology Innovation Platform
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(37,639)	(22,558)	(65,985)	(83,836)
Global Supply Chain Platform
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(6,089)	(1,564)	(16,780)	(4,693)
Commercial Platform
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (2,443)	$ 848	$ (7,562)	$ (14,358)

Business Segment, Geographic,_5

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Segments (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total revenue:
Total consolidated revenue	$ 18,428	$ 13,994	$ 67,829	$ 23,170
Operating Segments
Total revenue:
Total consolidated revenue	19,524	16,184	71,529	29,889
Operating Segments | Oncology Innovation Platform
Total revenue:
Total consolidated revenue	5,117	205	30,532	1,208
Operating Segments | Global Supply Chain Platform
Total revenue:
Total consolidated revenue	7,092	8,601	17,991	19,407
Operating Segments | Commercial Platform
Total revenue:
Total consolidated revenue	7,315	7,378	23,006	9,274
Intersegment Eliminations
Total revenue:
Total consolidated revenue	$ (1,096)	$ (2,190)	$ (3,700)	$ (6,719)

Business Segment, Geographic,_6

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Product Group (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total revenue by product group:
Total consolidated revenue	$ 18,428	$ 13,994	$ 67,829	$ 23,170
API Sales
Total revenue by product group:
Total consolidated revenue	3,690	5,345	9,538	10,369
Medical Device Sales
Total revenue by product group:
Total consolidated revenue	1,322	562	2,342	1,128
Contract Manufacturing Revenue
Total revenue by product group:
Total consolidated revenue	17	250	412	934
Commercial Product Sales
Total revenue by product group:
Total consolidated revenue	8,280	7,505	25,092	9,547
License Fees
Total revenue by product group:
Total consolidated revenue	5,000		30,000	500
Consulting Revenue
Total revenue by product group:
Total consolidated revenue	96	60	278	256
Grant Revenue
Total revenue by product group:
Total consolidated revenue	$ 23	$ 272	$ 167	$ 436

Business Segment, Geographic,_7

Business Segment, Geographic, and Concentration Risk Information - Summary of Depreciation, Amortization and Assets by Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Total depreciation and amortization:
Total consolidated depreciation and amortization	$ 909	$ 921	$ 2,424	$ 2,585
Total assets:
Total consolidated assets	244,467		244,467		$ 140,413
Oncology Innovation Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	174	130	505	342
Total assets:
Total consolidated assets	164,480		164,480		65,966
Global Supply Chain Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	490	548	1,185	1,569
Total assets:
Total consolidated assets	51,327		51,327		51,128
Commercial Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	245	$ 243	734	$ 674
Total assets:
Total consolidated assets	$ 28,660		$ 28,660		$ 23,319

Business Segment, Geographic,_8

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Geographical Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Total revenue:
Total consolidated revenue	$ 18,428	$ 13,994	$ 67,829	$ 23,170
United States
Total revenue:
Total consolidated revenue	9,559	8,114	27,405	11,056
Spain
Total revenue:
Total consolidated revenue	5,000		30,000
India
Total revenue:
Total consolidated revenue	259	3,015	1,701	5,275
Austria
Total revenue:
Total consolidated revenue	2,227	964	5,102	2,682
China
Total revenue:
Total consolidated revenue	306	1,038	1,917	2,267
Other Foreign Countries
Total revenue:
Total consolidated revenue	$ 1,077	$ 863	$ 1,704	$ 1,890

Business Segment, Geographic,_9

Business Segment, Geographic, and Concentration Risk Information - Summary of Property and Equipment by Geographical Segment (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Total property and equipment, net:
Total consolidated property and equipment, net	$ 11,174	$ 9,651
United States
Total property and equipment, net:
Total consolidated property and equipment, net	6,458	5,305
China
Total property and equipment, net:
Total consolidated property and equipment, net	$ 4,716	$ 4,346

Business Segment, Geographic_10

Business Segment, Geographic, and Concentration Risk Information - Summary of Customer Revenue and Accounts Receivable Concentration (Detail) - Commercial Platform and Global Supply Chain - Customer Concentration Risk	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Customer Revenue | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	27.00%		44.00%
Customer Revenue | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	13.00%	5.00%	9.00%	4.00%
Customer Revenue | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage	12.00%	16.00%	13.00%	11.00%
Customer Revenue | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage	11.00%	5.00%	8.00%	3.00%
Customer Revenue | Customer E
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	7.00%	6.00%	11.00%
Customer Revenue | Customer F
Concentration Risk [Line Items]
Concentration risk, percentage	1.00%	18.00%	2.00%	20.00%
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage			27.00%		18.00%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage			20.00%		10.00%
Accounts Receivable | Customer C
Concentration Risk [Line Items]
Concentration risk, percentage			13.00%		6.00%
Accounts Receivable | Customer D
Concentration Risk [Line Items]
Concentration risk, percentage			10.00%		4.00%
Accounts Receivable | Customer E
Concentration Risk [Line Items]
Concentration risk, percentage					26.00%
Accounts Receivable | Customer F
Concentration Risk [Line Items]
Concentration risk, percentage					13.00%

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue	$ 18,428	$ 13,994	$ 67,829	$ 23,170
Total chargebacks and other deductions					$ 3,795
Revenue recognition cash discount percentage	2.00%		2.00%
General settlement period for rebates and fees			Settlement of rebates and fees may generally occur from one to five months from date of sale.
Deferred revenue	$ 364		$ 364		1,202
Out-license Revenue
Revenue Recognition Milestone Method [Line Items]
Deferred revenue	400		400
Commercial Platform
Revenue Recognition Milestone Method [Line Items]
Total chargebacks and other deductions	13,200		13,200		$ 3,711
Chargebacks and other deductions expense	10,600	3,300	22,700	5,100
Transferred at a Point in Time
Revenue Recognition Milestone Method [Line Items]
Revenue recognized on behalf of milestone event				500
Transferred at a Point in Time | Commercial Platform
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue	7,315	7,378	23,006	9,274
IP License | Transferred at a Point in Time
Revenue Recognition Milestone Method [Line Items]
License fees and consulting revenue	$ 5,000	$ 0	$ 30,000	$ 0

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Disaggregation Of Revenue [Line Items]
Total revenue	$ 18,428	$ 13,994	$ 67,829	$ 23,170
Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	5,117	205	30,532	1,208
Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	5,996	6,411	14,291	12,688
Commercial Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	7,315	7,378	23,006	9,274
United States
Disaggregation Of Revenue [Line Items]
Total revenue	9,559	8,114	27,405	11,055
United States | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	2,244	736	4,399	1,781
United States | Commercial Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	7,315	7,378	23,006	9,274
Spain
Disaggregation Of Revenue [Line Items]
Total revenue	5,000		30,000
Spain | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	5,000		30,000
India
Disaggregation Of Revenue [Line Items]
Total revenue	258	3,015	1,701	5,275
India | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	258	3,015	1,701	5,275
Austria
Disaggregation Of Revenue [Line Items]
Total revenue	2,227	964	5,102	2,682
Austria | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	2,227	964	5,102	2,682
China
Disaggregation Of Revenue [Line Items]
Total revenue	306	1,038	1,917	1,766
China | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	117	205	532	708
China | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	189	833	1,385	1,058
Other Foreign Countries
Disaggregation Of Revenue [Line Items]
Total revenue	1,077	863	1,704	2,392
Other Foreign Countries | Oncology Innovation Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue				500
Other Foreign Countries | Global Supply Chain Platform | Transferred at a Point in Time
Disaggregation Of Revenue [Line Items]
Total revenue	$ 1,077	$ 863	$ 1,704	$ 1,892

Revenue Recognition - Summary o

Revenue Recognition - Summary of Receivables and Contract Liabilities From Contracts with Customers (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Change In Contract With Customer Liability [Abstract]
Accounts receivable, gross	$ 20,252	$ 12,263
Chargebacks and other deductions	(13,154)	(3,711)
Allowance for doubtful accounts	(27)	(84)
Accounts receivable, net	7,071	8,468
Deferred revenue	364	1,202
Total contract liabilities	$ 364	$ 1,202

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Accounts Receivable Balances by Reportable Segments (Details) - USD ($) $ in Thousands	Sep. 30, 2018	Dec. 31, 2017
Accounts Receivable Balances By Reportable Segments [Line Items]
Accounts receivable, gross	$ 20,252	$ 12,263
Chargebacks and other deductions	(13,154)	(3,711)
Allowance for doubtful accounts	(27)	(84)
Allowance for doubtful accounts, chargebacks, andother deductions		(3,795)
Accounts receivable, net	7,071	8,468
Oncology Innovation Platform
Accounts Receivable Balances By Reportable Segments [Line Items]
Accounts receivable, gross	9	49
Accounts receivable, net	9	49
Global Supply Chain Platform
Accounts Receivable Balances By Reportable Segments [Line Items]
Accounts receivable, gross	3,369	4,553
Allowance for doubtful accounts	(27)
Allowance for doubtful accounts, chargebacks, andother deductions		(84)
Accounts receivable, net	3,342	4,469
Commercial Platform
Accounts Receivable Balances By Reportable Segments [Line Items]
Accounts receivable, gross	16,874	7,661
Chargebacks and other deductions	(13,154)
Allowance for doubtful accounts, chargebacks, andother deductions	(13,200)	(3,711)
Accounts receivable, net	$ 3,720	$ 3,950

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Payments Under Non-Cancelable Leases (Detail) $ in Thousands	Sep. 30, 2018USD ($)
Commitments And Contingencies Disclosure [Abstract]
2018 (remaining three months)	$ 712
2,019	2,383
2,020	2,247
2,021	1,844
2,022	1,802
Thereafter	4,672
Future minimum payments under non-cancelable leases	$ 13,660